New markers in pneumonia

Clinica Chimica Acta

Volumn 419, Issue , 2013, Pages 19-25

  Cheng, Chao Wen ^a   Chien, Ming Hsien ^a,b   Su, Shih Chi ^c   Yang, Shun Fa ^d,e  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^e CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Biomarkers; Inflammation response proteins; Pneumonia

Indexed keywords

AMYLOID P COMPONENT; ANTIBIOTIC AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; COPEPTIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROCORTISONE; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; PENTRAXIN 3; PROADRENOMEDULLIN; PROCALCITONIN; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1; TUMOR NECROSIS FACTOR ALPHA;

CLINICAL PRACTICE; ENZYME ACTIVITY; HAEMOPHILUS INFLUENZAE; HUMAN; NEISSERIA MENINGITIDIS; OUTCOME ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; STREPTOCOCCUS PNEUMONIAE;

BIOLOGICAL MARKERS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; PNEUMONIA;

EID: 84874371705     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2013.01.011     Document Type: Review

References (93)

1. Metlay J.P., Fine M.J. Testing strategies in the initial management of patients with community-acquired pneumonia. Ann Intern Med 2003, 138:109-118.
2. Anand N., Kollef M.H. The alphabet soup of pneumonia: CAP, HAP, HCAP, NHAP, and VAP. Semin Respir Crit Care Med 2009, 30:3-9.
3. Niederman M.S., Mandell L.A., Anzueto A., et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001, 163:1730-1754.
4. Garibaldi R.A. Epidemiology of community-acquired respiratory tract infections in adults. Incidence, etiology, and impact. Am J Med 1985, 78:32-37.
5. Jereb M., Kotar T. Usefulness of procalcitonin to differentiate typical from atypical community-acquired pneumonia. Wien Klin Wochenschr 2006, 118:170-174.
6. Lutfiyya M.N., Henley E., Chang L.F., Reyburn S.W. Diagnosis and treatment of community-acquired pneumonia. Am Fam Physician 2006, 73:442-450.
7. Syrjala H., Broas M., Suramo I., Ojala A., Lahde S. High-resolution computed tomography for the diagnosis of community-acquired pneumonia. Clin Infect Dis 1998, 27:358-363.
8. NCI Biomarker Available from:, [Accessed Oct 26 2012]. http://www.cancer.gov/dictionary?CdrID=45618.
9. Christ-Crain M., Opal S.M. Clinical review: the role of biomarkers in the diagnosis and management of community-acquired pneumonia. Crit Care 2010, 14:203.
10. Povoa P. Serum markers in community-acquired pneumonia and ventilator-associated pneumonia. Curr Opin Infect Dis 2008, 21:157-162.
11. Brakstad O.G., Aasbakk K., Maeland J.A. Detection of Staphylococcus aureus by polymerase chain reaction amplification of the nuc gene. J Clin Microbiol 1992, 30:1654-1660.
12. Greisen K., Loeffelholz M., Purohit A., Leong D. PCR primers and probes for the 16S rRNA gene of most species of pathogenic bacteria, including bacteria found in cerebrospinal fluid. J Clin Microbiol 1994, 32:335-351.
13. Wheeler J., Freeman R., Steward M., et al. Detection of pneumolysin in sputum. J Med Microbiol 1999, 48:863-866.
14. Abdeldaim G.M., Stralin K., Korsgaard J., Blomberg J., Welinder-Olsson C., Herrmann B. Multiplex quantitative PCR for detection of lower respiratory tract infection and meningitis caused by Streptococcus pneumoniae, Haemophilus influenzae and Neisseria meningitidis. BMC Microbiol 2010, 10:310.
15. Louie R.F., Tang Z., Albertson T.E., Cohen S., Tran N.K., Kost G.J. Multiplex polymerase chain reaction detection enhancement of bacteremia and fungemia. Crit Care Med 2008, 36:1487-1492.
16. Pugin J., Auckenthaler R., Delaspre O., van Gessel E., Suter P.M. Rapid diagnosis of gram negative pneumonia by assay of endotoxin in bronchoalveolar lavage fluid. Thorax 1992, 47:547-549.
17. Flanagan P.G., Jackson S.K., Findlay G. Diagnosis of gram negative, ventilator associated pneumonia by assaying endotoxin in bronchial lavage fluid. J Clin Pathol 2001, 54:107-110.
18. Torres A., Ramirez P., Montull B., Menendez R. Biomarkers and community-acquired pneumonia: tailoring management with biological data. Semin Respir Crit Care Med 2012, 33:266-271.
19. Fernandez-Serrano S., Dorca J., Coromines M., Carratala J., Gudiol F., Manresa F. Molecular inflammatory responses measured in blood of patients with severe community-acquired pneumonia. Clin Diagn Lab Immunol 2003, 10:813-820.
20. Antunes G., Evans S.A., Lordan J.L., Frew A.J. Systemic cytokine levels in community-acquired pneumonia and their association with disease severity. Eur Respir J 2002, 20:990-995.
21. Conway Morris A., Kefala K., Wilkinson T.S., et al. Diagnostic importance of pulmonary interleukin-1beta and interleukin-8 in ventilator-associated pneumonia. Thorax 2010, 65:201-207.
22. Johnston P., McAuley D.F., O'Kane C.M. Novel pulmonary biomarkers in the diagnosis of VAP. Thorax 2010, 65:190-192.
23. Moalli F., Jaillon S., Inforzato A., et al. Pathogen recognition by the long pentraxin PTX3. J Biomed Biotechnol 2011, 2011:830421.
24. Mantovani A., Garlanda C., Doni A., Bottazzi B. Pentraxins in innate immunity: from C-reactive protein to the long pentraxin PTX3. J Clin Immunol 2008, 28:1-13.
25. Povoa P. C-reactive protein: a valuable marker of sepsis. Intensive Care Med 2002, 28:235-243.
26. Tillett W.S., Francis T. Serological reactions in pneumonia with a non-protein somatic fraction of pneumococcus. J Exp Med 1930, 52:561-571.
27. Bottazzi B., Doni A., Garlanda C., Mantovani A. An integrated view of humoral innate immunity: pentraxins as a paradigm. Annu Rev Immunol 2010, 28:157-183.
28. Summah H., Qu J.M. Biomarkers: a definite plus in pneumonia. Mediators Inflamm 2009, 2009:675753.
29. Flanders S.A., Stein J., Shochat G., et al. Performance of a bedside C-reactive protein test in the diagnosis of community-acquired pneumonia in adults with acute cough. Am J Med 2004, 116:529-535.
30. Smith R.P., Lipworth B.J., Cree I.A., Spiers E.M., Winter J.H. C-reactive protein. A clinical marker in community-acquired pneumonia. Chest 1995, 108:1288-1291.
31. Stolz D., Christ-Crain M., Gencay M.M., et al. Diagnostic value of signs, symptoms and laboratory values in lower respiratory tract infection. Swiss Med Wkly 2006, 136:434-440.
32. Almirall J., Bolibar I., Toran P., et al. Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia. Chest 2004, 125:1335-1342.
33. Lehtomaki K., Leinonen M., Takala A., Hovi T., Herva E., Koskela M. Etiological diagnosis of pneumonia in military conscripts by combined use of bacterial culture and serological methods. Eur J Clin Microbiol Infect Dis 1988, 7:348-354.
34. Ten Oever J., Tromp M., Bleeker-Rovers C.P., et al. Combination of biomarkers for the discrimination between bacterial and viral lower respiratory tract infections. J Infect 2012, 65:490-495.
35. Moreno M.S., Nietmann H., Matias C.M., Lobo S.M. C-reactive protein: a tool in the follow-up of nosocomial pneumonia. J Infect 2010, 61:205-211.
36. Povoa P., Teixeira-Pinto A.M., Carneiro A.H. Portuguese Community-Acquired Sepsis Study Group S. C-reactive protein, an early marker of community-acquired sepsis resolution: a multi-center prospective observational study. Crit Care 2011, 15:R169.
37. Coelho L.M., Salluh J.I., Soares M., et al. Patterns of c-reactive protein RATIO response in severe community-acquired pneumonia: a cohort study. Crit Care 2012, 16:R53.
38. Napoleone E., di Santo A., Peri G., et al. The long pentraxin PTX3 up-regulates tissue factor in activated monocytes: another link between inflammation and clotting activation. J Leukoc Biol 2004, 76:203-209.
39. Bottazzi B., Bastone A., Doni A., et al. The long pentraxin PTX3 as a link among innate immunity, inflammation, and female fertility. J Leukoc Biol 2006, 79:909-912.
40. Muller B., Peri G., Doni A., et al. Circulating levels of the long pentraxin PTX3 correlate with severity of infection in critically ill patients. Crit Care Med 2001, 29:1404-1407.
41. Wagenaar J.F., Goris M.G., Gasem M.H., et al. Long pentraxin PTX3 is associated with mortality and disease severity in severe Leptospirosis. J Infect 2009, 58:425-432.
42. Sprong T., Peri G., Neeleman C., et al. Pentraxin 3 and C-reactive protein in severe meningococcal disease. Shock 2009, 31:28-32.
43. Huttunen R., Hurme M., Aittoniemi J., et al. High plasma level of long pentraxin 3 (PTX3) is associated with fatal disease in bacteremic patients: a prospective cohort study. PLoS One 2011, 6:e17653.
44. Kao S.J., Yang H.W., Tsao S.M., et al. Plasma long pentraxin 3 (PTX3) concentration is a novel marker of disease activity in patients with community-acquired pneumonia. Clin Chem Lab Med 2012 Nov, 8:1-7. 10.1515/cclm-2012-0459.
45. Joyce C.D., Fiscus R.R., Wang X., Dries D.J., Morris R.C., Prinz R.A. Calcitonin gene-related peptide levels are elevated in patients with sepsis. Surgery 1990, 108:1097-1101.
46. Reinhart K., Karzai W., Meisner M. Procalcitonin as a marker of the systemic inflammatory response to infection. Intensive Care Med 2000, 26:1193-1200.
47. Nylen E.S., Whang K.T., Snider R.H., Steinwald P.M., White J.C., Becker K.L. Mortality is increased by procalcitonin and decreased by an antiserum reactive to procalcitonin in experimental sepsis. Crit Care Med 1998, 26:1001-1006.
48. Lipinska-Gediga M., Mierzchala M., Durek G. Pro-atrial natriuretic peptide (pro-ANP) level in patients with severe sepsis and septic shock: prognostic and diagnostic significance. Infection 2012, 40:303-309.
49. Jensen J.U., Heslet L., Jensen T.H., Espersen K., Steffensen P., Tvede M. Procalcitonin increase in early identification of critically ill patients at high risk of mortality. Crit Care Med 2006, 34:2596-2602.
50. Muller B., Harbarth S., Stolz D., et al. Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia. BMC Infect Dis 2007, 7:10.
51. Ramirez P., Garcia M.A., Ferrer M., et al. Sequential measurements of procalcitonin levels in diagnosing ventilator-associated pneumonia. Eur Respir J 2008, 31:356-362.
52. Huang D.T., Weissfeld L.A., Kellum J.A., et al. Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia. Ann Emerg Med 2008, 52(48-58):e42.
53. Kruger S., Ewig S., Marre R., et al. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes. Eur Respir J 2008, 31:349-355.
54. Christ-Crain M., Stolz D., Bingisser R., et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006, 174:84-93.
55. Zudaire E., Portal-Nunez S., Cuttitta F. The central role of adrenomedullin in host defense. J Leukoc Biol 2006, 80:237-244.
56. Kangawa K., Kitamura K., Minamino N., Eto T., Matsuo H. Adrenomedullin: a new hypotensive peptide. J Hypertens Suppl 1996, 14:S105-S110.
57. Hirata Y., Mitaka C., Sato K., et al. Increased circulating adrenomedullin, a novel vasodilatory peptide, in sepsis. J Clin Endocrinol Metabol 1996, 81:1449-1453.
58. Isumi Y., Kubo A., Katafuchi T., Kangawa K., Minamino N. Adrenomedullin suppresses interleukin-1beta-induced tumor necrosis factor-alpha production in Swiss 3T3 cells. FEBS Lett 1999, 463:110-114.
59. Christ-Crain M., Morgenthaler N.G., Struck J., Harbarth S., Bergmann A., Muller B. Mid-regional pro-adrenomedullin as a prognostic marker in sepsis: an observational study. Crit Care 2005, 9:R816-R824.
60. Christ-Crain M., Morgenthaler N.G., Stolz D., et al. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTN04176397]. Crit Care 2006, 10:R96.
61. Sarda Sanchez M., Hernandez J.C., Hernandez-Bou S., Teruel G.C., Rodriguez J.V., Cubells C.L. Pro-adrenomedullin usefulness in the management of children with community-acquired pneumonia, a preliminar prospective observational study. BMC Res Notes 2012, 5:363.
62. Bouchon A., Facchetti F., Weigand M.A., Colonna M. TREM-1 amplifies inflammation and is a crucial mediator of septic shock. Nature 2001, 410:1103-1107.
63. Gibot S., Cravoisy A. Soluble form of the triggering receptor expressed on myeloid cells-1 as a marker of microbial infection. Clin Med Res 2004, 2:181-187.
64. Gibot S., Massin F., Marcou M., et al. TREM-1 promotes survival during septic shock in mice. Eur J Immunol 2007, 37:456-466.
65. Bouchon A., Dietrich J., Colonna M. Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. J Immunol 2000, 164:4991-4995.
66. Gibot S., Cravoisy A., Levy B., Bene M.C., Faure G., Bollaert P.E. Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia. N Engl J Med 2004, 350:451-458.
67. Oudhuis G.J., Beuving J., Bergmans D., et al. Soluble Triggering Receptor Expressed on Myeloid cells-1 in bronchoalveolar lavage fluid is not predictive for ventilator-associated pneumonia. Intensive Care Med 2009, 35:1265-1270.
68. Anand N.J., Zuick S., Klesney-Tait J., Kollef M.H. Diagnostic implications of soluble triggering receptor expressed on myeloid cells-1 in BAL fluid of patients with pulmonary infiltrates in the ICU. Chest 2009, 135:641-647.
69. Phua J., Koay E.S., Zhang D., et al. Soluble triggering receptor expressed on myeloid cells-1 in acute respiratory infections. Eur Respir J 2006, 28:695-702.
70. Katan M., Christ-Crain M. The stress hormone copeptin: a new prognostic biomarker in acute illness. Swiss Med Wkly 2010, 140:w13101.
71. Nickel C.H., Bingisser R., Morgenthaler N.G. The role of copeptin as a diagnostic and prognostic biomarker for risk stratification in the emergency department. BMC Med 2012, 10:7.
72. Land H., Schutz G., Schmale H., Richter D. Nucleotide sequence of cloned cDNA encoding bovine arginine vasopressin-neurophysin II precursor. Nature 1982, 295:299-303.
73. Morgenthaler N.G., Struck J., Alonso C., Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 2006, 52:112-119.
74. Morgenthaler N.G., Struck J., Jochberger S., Dunser M.W. Copeptin: clinical use of a new biomarker. Trends Endocrinol Metab 2008, 19:43-49.
75. Muller B., Morgenthaler N., Stolz D., et al. Circulating levels of copeptin, a novel biomarker, in lower respiratory tract infections. Eur J Clin Invest 2007, 37:145-152.
76. Kruger S., Ewig S., Kunde J., et al. Pro-atrial natriuretic peptide and pro-vasopressin for predicting short-term and long-term survival in community-acquired pneumonia: results from the German Competence Network CAPNETZ. Thorax 2010, 65:208-214.
77. Boeck L., Eggimann P., Smyrnios N., et al. The Sequential Organ Failure Assessment score and copeptin for predicting survival in ventilator-associated pneumonia. J Crit Care 2012, 27(523):e521-e529.
78. Seligman R., Papassotiriou J., Morgenthaler N.G., Meisner M., Teixeira P.J. Copeptin, a novel prognostic biomarker in ventilator-associated pneumonia. Crit Care 2008, 12:R11.
79. Dubey A., Boujoukos A.J. Measurements of serum free cortisol in critically ill patients. Crit Care 2005, 9:E2.
80. Hamrahian A.H., Oseni T.S., Arafah B.M. Measurements of serum free cortisol in critically ill patients. N Engl J Med 2004, 350:1629-1638.
81. Christ-Crain M., Stolz D., Jutla S., et al. Free and total cortisol levels as predictors of severity and outcome in community-acquired pneumonia. Am J Respir Crit Care Med 2007, 176:913-920.
82. Kolditz M., Hoffken G., Martus P., et al. Serum cortisol predicts death and critical disease independently of CRB-65 score in community-acquired pneumonia: a prospective observational cohort study. BMC Infect Dis 2012, 12:90.
83. Seligman R., Papassotiriou J., Morgenthaler N.G., Meisner M., Teixeira P.J. Prognostic value of midregional pro-atrial natriuretic peptide in ventilator-associated pneumonia. Intensive Care Med 2008, 34:2084-2091.
84. Prat C., Lacoma A., Dominguez J., et al. Midregional pro-atrial natriuretic peptide as a prognostic marker in pneumonia. J Infect 2007, 55:400-407.
85. Christ-Crain M., Breidthardt T., Stolz D., et al. Use of B-type natriuretic peptide in the risk stratification of community-acquired pneumonia. J Intern Med 2008, 264:166-176.
86. Yetkin O., Hacievliyagil S.S., Gunen H. Assessment of B-type natriuretic peptide in patients with pneumonia. Int J Clin Pract 2008, 62:488-491.
87. Mueller C., Laule-Kilian K., Scholer A., Perruchoud A.P. B-type natriuretic peptide for risk stratification in community-acquired pneumonia. J Intern Med 2005, 258:391-393.
88. Braun E., Domany E., Kenig Y., Mazor Y., Makhoul B.F., Azzam Z.S. Elevated red cell distribution width predicts poor outcome in young patients with community acquired pneumonia. Crit Care 2011, 15:R194.
89. Weston A.D., Hood L. Systems biology, proteomics, and the future of health care: toward predictive, preventative, and personalized medicine. J Proteome Res 2004, 3:179-196.
90. Yip T.T., Chan J.W., Cho W.C., et al. Protein chip array profiling analysis in patients with severe acute respiratory syndrome identified serum amyloid a protein as a biomarker potentially useful in monitoring the extent of pneumonia. Clin Chem 2005, 51:47-55.
91. Tsai M.H., Lin T.Y., Hsieh S.Y., Chiu C.Y., Chiu C.H., Huang Y.C. Comparative proteomic studies of plasma from children with pneumococcal pneumonia. Scand J Infect Dis 2009, 41:416-424.
92. Slupsky C.M., Rankin K.N., Fu H., et al. Pneumococcal pneumonia: potential for diagnosis through a urinary metabolic profile. J Proteome Res 2009, 8:5550-5558.
93. Laiakis E.C., Morris G.A., Fornace A.J., Howie S.R. Metabolomic analysis in severe childhood pneumonia in the Gambia, West Africa: findings from a pilot study. PLoS One 2010, 5.